ClinicalTrials.gg
Active, not recruitingNCT05094336MTAPESTRY 101Updated May 28, 2026

A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)

A Phase 1/2 interventional study of Anvumetostat and Docetaxel in Advanced MTAP-null Solid Tumors, sponsored by Amgen. Active, not recruiting at 75 sites in 14 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-05-28.

Sponsored by Amgen · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
329
Allocation
Non-randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 40 studies in Carcinoma, Non-Small-Cell Lung by Amgen — 2 open to participants now, 7 under way, 4 of them phase 3. Carcinoma, Non-Small-Cell Lung · Amgen.

Enrollment
6th of 31
329 · median 145
Started
2022
with 2 others
Phase 1/2
5 of 40
none open now
Registered
32nd of 40
by date

Among the 40 studies in Carcinoma, Non-Small-Cell Lung by Amgen, this one is the 6th largest by enrollment of the 31 interventional ones that give a count, is one of 3 that started in 2022, is one of 5 in phase 1/2, and was the 32nd registered.

Carcinoma, Non-Small-Cell Lung

7,635 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

2 of the 40 studies in Carcinoma, Non-Small-Cell Lung by Amgen are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Carcinoma, Non-Small-Cell Lung by Amgen, or all of them as a file.
02

Study summary

The primary objective of Parts 1 and 2 of this study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of Anvumetostat alone and in combination with docetaxel in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors.

The primary objective of Part 3 of this study is to evaluate the efficacy of Anvumetostat in adult participants with metastatic or locally advanced MTAP-null solid tumors.

03

Conditions studied

  • Advanced MTAP-null Solid Tumors

Keywords

  • Metastatic MTAP-null solid tumors
  • Advanced MTAP-null solid tumors
  • Non-small cell lung cancer
  • Biliary Tract Cancer (BTC)
  • Head and neck squamous cell carcinoma
  • Pancreatic adenocarcinoma
  • Esophageal cancer
  • Gastric cancer
  • Glioma
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has provided /assent before initiation of any study specific activities/procedures.
  • Age ≥ 18 years.
  • Evidence of homozygous loss of cyclin dependent kinase inhibitor 2A (CDKN2A) (null) (Parts 1a, 1j, 1k, and 2a only) and/or methylthioadenosine phosphorylase (MTAP) (null) in the tumor tissue or blood (Parts 1a to 1k, Parts 2a and 2b) or lost MTAP expression in the tumor tissue (Parts 1a to 1k, Parts 2a and 2b).
  • confirmed or locally advanced solid tumor not amenable to curative treatment with surgery and/or radiation.
  • Able to swallow and retain orally (PO) administered study treatment and willing to record daily adherence to product.
  • Disease measurable as defined by Version 1.1 (RECIST v1.1). Note: except participants enrolling to Part 1m.
  • (ECOG) performance status of 0 to 1.
  • Adequate hematopoietic function per local laboratory
  • Adequate renal function per local laboratory
  • Adequate glucose control per local laboratory (Part 1 only)
  • Adequate liver function per local laboratory
  • Adequate coagulation parameters
  • Adequate pulmonary function
  • Adequate cardiac function
  • Minimum of 12 weeks as per investigator judgement.
  • Archived tumor tissue (formalin-fixed, paraffin-embedded [FFPE] sample collected within 5 years) or an must be available.
  • For Part 1f (MTAP-null or lost MTAP expression HNSCC): Must be willing to undergo tumor biopsy.
  • For Part 1a: Must be willing to undergo tumor biopsy, before start of treatment (archival sample acceptable if obtained with 6 months of enrollment and subject has not received any other treatment since sample was obtained) and while on treatment.
  • For DSPS study (Part 1j): Must be willing to participate in DSPS substudy (US sites only).

Food Effect Substudy (Part 1k): Specific Inclusion Criteria

  • Subject able and willing to eat a standardized high-fat, high-caloric meal
  • Subject able and willing to fast for ≥ 6 hours

Specific Inclusion Criteria for subjects with glioma (Part 1m only)

- Disease measurable as defined per Modified Response Assessment in Neuro-Oncology Criteria 2.0 (mRANO 2.0)

Exclusion criteria

Exclusion Criteria:

  • Spinal cord compression or untreated or .
  • History of other within the past 2 years
  • Any evidence of current interstitial lung disease
  • Active infection
  • Evidence of active severe acute respiratory syndrome coronavirus 2 (SARS-COV2) infection.
  • History of arterial thrombosis
  • Myocardial infarction and/or symptomatic congestive heart failure.
  • Gastrointestinal tract disease
  • History of bowel obstruction, abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess
  • History of solid organ transplant.
  • Diagnosis of Congenital Short Syndrome.
  • Major surgery
  • Anti-tumor therapy within 28 days of study day 1.
  • Prior treatment with an methionine adenosyltransferase 2α (MAT2A) inhibitor or a protein arginine methyltransferase 5 (PRMT5) inhibitor.
  • Prior treatment with docetaxel (Part 2 only)
  • Prior irradiation to 25% of the bone marrow.
  • Therapeutic or palliative radiation therapy within 2 weeks of study day 1.
  • therapy within 4 weeks before study drug administration.
  • Use of therapeutic anti-coagulation for treatment of active thromboembolic events.
  • Use of prescription medications that are known strong inducers of cytochrome P450 3A4 () within 14 days or 5 half-lives (whichever is longer) before study day 1
  • Unresolved toxicity from prior anti-cancer therapy
  • Currently receiving treatment in another device or drug study.
  • Known positive test for (HIV).
  • Positive surface antigen
  • positive virus ribonucleic acid (RNA) by polymerase chain reaction (PCR)
  • Female participants of unwilling to use protocol specified method of
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
329 participants (actual)

Study arms

  • Experimental
    Part 1a, Phase 1: Anvumetostat Monotherapy Dose Exploration

    Participants with MTAP-null solid tumors will receive escalating doses of Anvumetostat to estimate the MTD and/or the RP2D.

    Drug: Anvumetostat

  • Experimental
    Part 1c, Phase 1: Anvumetostat Monotherapy Dose Expansion

    Participants will receive the identified MTD/RP2D of Anvumetostat in the following cohort: MTAP-null NSCLC.

    Drug: Anvumetostat

  • Experimental
    Part 2a, Phase 1: Anvumetostat Dose Exploration + Docetaxel

    Participants with MTAP-null NSCLC will receive escalating doses of Anvumetostat + a fixed dose of docetaxel to estimate the MTD/RP2D of the combination.

    Drug: Anvumetostat · Drug: Docetaxel

  • Experimental
    Part 2b, Phase 1: Anvumetostat + Docetaxel Dose Expansion

    Participants with MTAP-null NSCLC will receive the identified MTD/RP2D of Anvumetostat + docetaxel.

    Drug: Anvumetostat · Drug: Docetaxel

  • Experimental
    Part 3: Anvumetostat Phase 2

    Participants with MTAP-null solid tumors will receive Anvumetostat.

    Drug: Anvumetostat

  • Experimental
    Part 1e, Phase 1: Anvumetostat Monotherapy Dose Expansion

    Participants will receive the identified selected dose/MTD of Anvumetostat in the following cohort: MTAP-null BTC.

    Drug: Anvumetostat

  • Experimental
    Part 1f, Phase 1: Anvumetostat Monotherapy Dose Expansion

    Participants will receive the identified selected dose/MTD of Anvumetostat in the following cohort: MTAP-null head and neck squamous cell carcinoma (HNSCC).

    Drug: Anvumetostat

  • Experimental
    Part 1g, Phase 1: Anvumetostat Monotherapy Dose Expansion

    Participants will receive the identified selected dose/MTD of Anvumetostat in the following cohort: MTAP-null pancreatic adenocarcinoma.

    Drug: Anvumetostat

  • Experimental
    Part 1h, Phase 1: Anvumetostat Monotherapy Dose Expansion

    Participants will receive the identified selected dose/MTD of Anvumetostat in the following cohort: MTAP-null or lost MTAP expression solid tumors (other than lymphoma or primary brain tumor).

    Drug: Anvumetostat

  • Experimental
    Part 1i, Phase 1: Anvumetostat Dose Optimization

    Participants will receive a randomized dose optimization evaluation of Anvumetostat.

    Drug: Anvumetostat

  • Experimental
    Part 1j, Phase 1: Anvumetostat DSPS Substudy (US Sites Only)

    Participants will receive doses of Anvumetostat and comparator Anvumetostat test tables at different times in a fasted state.

    Drug: Anvumetostat · Drug: Comparator Anvumetostat Test Tablet

  • Experimental
    Part 1k, Phase 1: Anvumetostat Food Effect Substudy (US Sites Only)

    Participants will receive Anvumetostat once on a fasted state and once after eating a standardized high-fat, high calorie meal.

    Drug: Anvumetostat

  • Experimental
    Part 1l, Phase 1: Anvumetostat Monotherapy Dose Expansion

    Participants will receive the identified selected dose/MTD of Anvumetostat in the following cohort: MTAP-null esophageal/gastric cancer.

    Drug: Anvumetostat

  • Experimental
    Part 1m, Phase 1: Anvumetostat Monotherapy Dose Expansion

    Participants will receive the identified selected dose/MTD of Anvumetostat in the following cohort: MTAP-null glioma.

    Drug: Anvumetostat

Interventions

  • Anvumetostat: Orally via tablet

    Also known as: MTA Cooperative PRMT5 inhibitor, AMG 193

  • Docetaxel: Intravenous infusion

  • DrugComparator Anvumetostat Test Tablet

    Comparator Anvumetostat test tablet: Orally via tablet. Only participants in the DSPS group of the Part 1a, Phase 1: Anvumetostat Monotherapy Dose Exploration, and Part 1j, Phase 1 arms will receive comparator Anvumetostat test tablet.

06

What researchers measure

Primary outcomes

  1. Parts 1 and 2: Number of Participants Who Experience a Dose-Limiting Toxicity (DLT)

    Time frame: 28 days

  2. Parts 1 and 2: Number of Participants Who Experience a Treatment-emergent Adverse Event (TEAE)

    Adverse events (AEs) are defined as any untoward medical occurrence in clinical study participant irrespective of a causal relationship with the study treatment. TEAEs are any event that occurs after the participant has received study treatment. Any clinically significant changes in vital signs, electrocardiograms (ECGs) and clinical laboratory tests will be recorded as TEAEs. Serious AEs (SAEs) are defined as any event that meets at least 1 of the following serious criteria: * Results in death (fatal) * Requires in-patient hospitalization or prolongation of existing hospitalization * Results in persistent or significant disability/incapacity * Is a congenital anomaly/birth defect * Other medically important serious event

    Time frame: Up to approximately 3 years

  3. Part 3: Objective Response Rate (ORR)

    Time frame: Up to approximately 3 years

Secondary outcomes

  1. Parts 1 and 2: Maximal Plasma Concentration (Cmax) of Anvumetostat

    Time frame: Cycle 1 Day 1 to Pre-Dose Cycle 5 Day 1 (Part 1 Cycle = 28 days, Part 2 Cycle =21 days)

  2. Parts 1 and 2: Time to Achieve Maximal Plasma Concentration (Tmax) of Anvumetostat

    Time frame: Cycle 1 Day 1 to Pre-Dose Cycle 5 Day 1 (Part 1 Cycle = 28 days, Part 2 Cycle =21 days)

  3. Parts 1 and 2: Area Under the Plasma Concentration Versus Time Curve (AUC) of Anvumetostat

    Time frame: Cycle 1 Day 1 to Pre-Dose Cycle 5 Day 1 (Part 1 Cycle = 28 days, Part 2 Cycle =21 days)

  4. Part 2 Only: Maximal Plasma Concentration (Cmax) of Docetaxel

    Time frame: Cycle 1 Day 1 to Pre-Dose Cycle 5 Day 1 (Cycle =21 days)

  5. Part 2 Only: Time to Achieve Maximal Plasma Concentration (Tmax) of Docetaxel

    Time frame: Cycle 1 Day 1 to Pre-Dose Cycle 5 Day 1 (Cycle =21 days)

  6. Part 2 Only: Area Under the Plasma Concentration Versus Time Curve (AUC) of Docetaxel

    Time frame: Cycle 1 Day 1 to Pre-Dose Cycle 5 Day 1 (Cycle =21 days)

  7. Parts 1 and 2: ORR

    Time frame: Up to approximately 3 years

  8. Parts 1, 2 and 3: Disease Control Rate (DCR)

    Time frame: Up to approximately 3 years

  9. Parts 1, 2 and 3: Duration of Response (DoR)

    Time frame: Up to approximately 3 years

  10. Parts 1, 2 and 3: Time to Response (TTR)

    Time frame: Up to approximately 3 years

  11. Parts 1, 2 and 3: Duration of Disease Control (DC)

    Time frame: Up to approximately 3 years

  12. Parts 1, 2 and 3: Progression-Free Survival (PFS)

    Time frame: Up to approximately 3 years

  13. Parts 1, 2 and 3: Overall Survival (OS)

    Time frame: Up to approximately 5 years

  14. Part 3 Only: Number of Participants Who Experience TEAE

    AEs are defined as any untoward medical occurrence in clinical study participant irrespective of a causal relationship with the study treatment. TEAEs are any event that occurs after the participant has received study treatment. Any clinically significant changes in vital signs, ECGs and clinical laboratory tests will be recorded as TEAEs. SAEs are defined as any event that meets at least 1 of the following serious criteria: * Results in death (fatal) * Requires in-patient hospitalization or prolongation of existing hospitalization * Results in persistent or significant disability/incapacity * Is a congenital anomaly/birth defect * Other medically important serious event

    Time frame: Up to approximately 3 years

  15. Part 1a Only: Maximal Plasma Concentration (Cmax) of Anvumetostat

    Time frame: Cycle 2 Day 1 to pre-dose on Cycle 2 Day 2 (Cycle = 28 days)

  16. Part 1a Only: Time to Achieve Maximal Plasma Concentration (Tmax) of Anvumetostat

    Time frame: Cycle 2 Day 1 to pre-dose on Cycle 2 Day 2 (Cycle = 28 days)

  17. Part 1a Only: Area Under the Plasma Concentration Versus Time Curve (AUC) of Anvumetostat

    Time frame: Cycle 2 Day 1 to pre-dose on Cycle 2 Day 2 (Cycle = 28 days)

  18. Part 1a Only: Maximal Plasma Concentration (Cmax) of Comparator Anvumetostat Test Tablet

    Time frame: Cycle 2 Day 2 to pre-dose on Cycle 2 Day 3 (Cycle = 28 days)

  19. Part 1a Only: Time to Achieve Maximal Plasma Concentration (Tmax) of Comparator Anvumetostat Test Tablet

    Time frame: Cycle 2 Day 2 to pre-dose on Cycle 2 Day 3 (Cycle = 28 days)

  20. Part 1a Only: Area Under the Plasma Concentration Versus Time Curve (AUC) of Comparator Anvumetostat Test Tablet

    Time frame: Cycle 2 Day 2 to pre-dose on Cycle 2 Day 3 (Cycle = 28 days)

  21. Part 1k Only: Cmax of Anvumetostat during fasted state

    Time frame: Cycle 2 day 1 pre-dose up to 24 hours post-dose (Cycle = 28 days)

  22. Part 1k Only: Tmax of Anvumetostat during fasted state

    Time frame: Cycle 2 day 1 pre-dose up to 24 hours post-dose (Cycle = 28 days)

  23. Part 1k Only: AUC of Anvumetostat during fasted state

    Time frame: Cycle 2 day 1 pre-dose up to 24 hours post-dose (Cycle = 28 days)

  24. Part 1k Only: Cmax of Anvumetostat during fed state

    Time frame: Cycle 2 day 2 pre-dose up to 24 hours post-dose (Cycle = 28 days)

  25. Part 1k Only: Tmax of Anvumetostat during fed state

    Time frame: Cycle 2 day 2 pre-dose up to 24 hours post-dose (Cycle = 28 days)

  26. Part 1k Only: AUC of Anvumetostat during fed state

    Time frame: Cycle 2 day 2 pre-dose up to 24 hours post-dose (Cycle = 28 days)

07

Study locations

75 sites
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2022 (actual). Primary completion is estimated for Nov 2026, 57 months after the start.

Of 312 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's planned 57 months is close to that.

Counting every sponsor, half of 435 studies reached it within 63 months; a quarter within 41 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2021
First posted
Oct 26, 2021
StartActual
Feb 1, 2022
Primary completionEst.
Nov 30, 2026
CompletionEst.
Nov 30, 2026
Last update
May 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05094336
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Oct 26, 2021
Start date
Feb 1, 2022
Primary completion
Nov 30, 2026 (estimated)
Completion
Nov 30, 2026 (estimated)
Last update
May 28, 2026

Study contacts

MD
study director · Amgen

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anvumetostat

Start the discussion